Geriatric Assessment Finds Older and Younger Adults With PTCL Had Similar Outcomes

News
Video

Tetiana Skrypets, MD, highlighted that older adults with PTCL may be treated as younger adults if they pass the geriatric assessment.

During the 2025 European Hematology Association Congress, CancerNetwork® spoke with Tetiana Skrypets, MD, regarding a geriatric assessment conducted for elderly patients with peripheral T-cell lymphoma.1

The trial did not find any clinical differences in the 65 to 74 years cohort and the 75 years or older cohort, which investigators determined could mean the groups had biologically similar disease. The median follow-up was 40.3 months (95% CI, 36.7-43.8), and the 2-year overall survival was 44.8% and the 5-year was 33.8%. For the same time points, the progression-free survival was 28.1% and 21.5%, respectively.

Overall, Skrypets, a clinical research physician at the Istituto Tumori Giovanni Paolo II in Bari, Italy, noted that with these results, she hopes to create a geriatric assessment for this group of patients.

Transcript:

We have to evaluate these patients better than we’re doing now, because we have these limits, like age. [Many] colleagues think that when a patient is 65 or more years old, the approach [used] is for elderly patients, but not all elderly patients, even at the age of 70 or 75 years old, are the same. Some of them could be treated in a more aggressive way. For some of them, we still have to think about the autologous transplant approach as a consolidation therapy after the frontline therapy. We also need some geriatric assessment, like it was done for B cell lymphomas by the Italian group, published by Drs Merli and Luminari, the name is EPI score.2 In the future, with this cohort of patients, we will be able to produce a particular geriatric assessment for this group of patients.

References

  1. Skrypets T, Conte L, Alpdogan, et al. Peripheral T-cell lymphoma in the elderly: Report on 922 patients from the T-Cell Project 1.0 and 2.0. Presented at the 2025 European Hematology Association Congress, Milan Italy, June 12-15, 2025. Abstract 19.
  2. Merli F, Luminari S, Tucci A, et al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi. J Clin Oncol. 2021;39(11):1214-1222. doi:10.1200/JCO.20.02465

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content